Chugai's Anti-IL-31 Receptor A Humanized Monoclonal Antibody "nemolizumab," Long Term Data from Global Phase II Study Published in Journal of Allergy and Clinical Immunology Online
Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that the
long-term data from a global phase II study (the XCIMA study) for
nemolizumab (CIM331) was published in Journal of Allergy and Clinical
Immunology Online on May 9, 2018.
“Nemolizumab in moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study” Kenji Kabashima, M.D., Ph.D., et al
“Control of chronic pruritus and inflammation of the skin is crucial for patients with atopic dermatitis (AD). This long-term extension data which demonstrated efficacy and safety of nemolizumab reinforced anticipation that nemolizumab may offer a novel treatment option for the disease,” said Dr. Yasushi Ito, Executive Vice President, Co-Head of Project & Lifecycle Management Unit. “Chugai’s mission is to contribute to patients through innovative medicines. We will closely work together with our partners - Galderma and Maruho, towards helping AD patients by developing this new treatment option as quickly as possible.”
“I am delighted to see a steady development of the novel treatment which addresses pathogenesis of pruritus in atopic dermatitis,” said, Professor Kenji Kabashima, Kyoto University, the first author of the article. “I would like to carefully examine safety and efficacy of nemolizumab further, in the expectation of future clinical use.”
The study was conducted to evaluate safety and efficacy of nemolizumab in 264 patients with moderate-to-severe AD. The safety and efficacy of nemolizumab at 12 weeks, the study’s primary endpoint, were confirmed and published in The New England Journal of Medicine Online in March 2017. The data published this time was obtained to assess safety and efficacy of long-term administration. It confirmed that nemolizumab maintained its safety and efficacy after one year of continuous treatment.
About the results of the global phase II study
Press release issued in March 2, 2017.
Chugai granted the exclusive development and marketing rights of nemolizumab worldwide, excluding Japan and Taiwan, to Galderma and licensed out the development and marketing rights in the skin disease area to Maruho for the Japanese market respectively. Currently, Galderma is conducting a phase 2b study and Maruho is conducting a phase 3 study.
Please refer to the press release for the details of the license
About nemolizumab (CIM331)
Nemolizumab (CIM331) is a humanized anti-human IL-31 receptor A (IL-31RA) monoclonal antibody intending to be a first-in-class treatment. IL-31 is identified as a pro-inflammatory cytokine that can induce pruritus, inflammation, and skin barrier dysfunction in atopic dermatitis, as well as pruritus in dialysis patients1, 2, 3, 4). Nemolizumab is thought to work by inhibiting biological activity of IL-31 through competitively blocking the binding of IL-31 to its receptor.
Trademarks used or mentioned in this release are protected by law.
1. Sonkoly E, et al., IL-31: A new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006; 117: 411-7.
2. Cornelissen C, et al., IL-31 regulates differentiation and filaggrin expression in human organotypic skin models. J Allergy Clinical Immunol 2012; 129: 426-33.
3. Kasraie S, et al., Interleukin (IL)-31 induces pro-inflammatory cytokines in human monocytes and macrophages following stimulation with staphylococcal exotoxins. Allergy 2010; 65: 712-21.
4. Ko MJ, et al., Interleukin-31 is associated with uremic pruritus in patients receiving hemodialysis. J Am Acad Dermatol 2014; 71: 1151-9.
Chugai Pharmaceutical Co., Ltd.
Media Relations Group, Corporate Communications Dept.,
For US media
Chugai Pharma USA Inc.
For European media
Chugai Pharma France SAS
For Taiwanese media
Chugai Pharma Taiwan Ltd.
Chugai Pharmaceutical Co., Ltd.
Investor Relations Group, Corporate Communications Dept.,
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Samsung Bioepis Announces Results of Additional One-Year Follow-Up Study Comparing Event-Free Survival of SB3 Trastuzumab Biosimilar Candidate to Reference Trastuzumab by ADCC Activity8.12.2018 14:10 | Pressemelding
Samsung Bioepis Co., Ltd. today announced the results of an additional one-year follow-up study comparing event-free survival (EFS) of SB3, a biosimilar candidate referencing HERCEPTIN® 1 (trastuzumab), to reference trastuzumab (TRZ) by antibody-dependent cell-mediated cytotoxicity (ADCC) activity. ADCC is a key mechanism of action for trastuzumab. The study results are being presented at the 2018 San Antonio Breast Cancer Symposium® (SABCS) which is being held December 4-8, 2018 in San Antonio, Texas. For the study, patients with HER2 positive early or locally advanced breast cancer were randomly assigned to receive SB3 or TRZ concurrently with chemotherapy. Patients then underwent surgery followed by treatment with SB3 or TRZ. Following completion of such therapy, 367 patients participated in a long-term follow-up study, 186 of whom were treated with SB3 and 181 of whom were treated with TRZ. Within the group of 181 patients who received TRZ, 126 patients who were exposed to at least
Harvest Health & Recreation, Inc. to hold Conference Call to Discuss Q3 2018 Results and Performance Outlook7.12.2018 19:00 | Pressemelding
Harvest Health & Recreation, Inc. (HARV: CSE) will hold its Third Quarter 2018 earnings conference call on: Tuesday, December 11, 2018 8:30 AM (Eastern Time) Participating on the call to review Harvest Health & Recreation’s Third Quarter 2018 financial and operating results will be Jason Vedadi, Executive Chairman, Steve White, Chief Executive Officer, and Steve Gutterman, President. Third quarter results are available at www.harvestinc.com/news. To participate in the conference call, please dial: US toll free +1-866-777-2509 Canada toll free +1-866-605-3852 UK toll free +44-080-823-89064 International dial in +1-412-317-5413 Registration is required; please dial in at least ten minutes prior to the scheduled start time. Webcast: https://services.choruscall.com/links/harv181211.html The conference call will be available for replay for 3 months at: https://services.choruscall.com/links/harv181211.html. About Harvest Health & Recreation, Inc. Harvest Health & Recreation, Inc. is one of t
David Hall Wows Industry with New Technology Solution for Space Exploration7.12.2018 14:01 | Pressemelding
David Hall is one of history’s rare technological visionaries with the imagination and technical wherewithal to recognize a problem, conceive a solution, and then build something that works. On December 6 at the U.S. Chamber of Commerce’s event, LAUNCH: Industry Taking Off, David Hall presented his world-changing solution to a longstanding problem: how to carry materials and people into space safely, reliably, and efficiently. The audience of industry, military, and policy representatives heard from Hall as well as keynote remarks from Secretary of the Air Force, Heather Wilson; NASA Administrator, Jim Bridenstine; Under Secretary of Defense for Research and Engineering, Michael Griffin; NOAA Deputy Administrator, Dr. Neil Jacobs; and Commerce Secretary, Wilbur Ross. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181207005226/en/ Velodyne Lidar, Inc. Founder and CEO David Hall (Photo: Business Wire) Hall’s proposal involves
Raj Subramaniam Named as FedEx Express President and CEO7.12.2018 14:00 | Pressemelding
FedEx Corp. (NYSE:FDX) announced today that David L. Cunningham, president and chief executive officer of FedEx Express, will retire effective December 31, 2018. Raj Subramaniam, currently executive vice president, chief marketing and communications officer of FedEx Corporation, will succeed Cunningham effective January 1, 2019. Cunningham began his FedEx career in 1982 in operations at the FedEx Express World Hub in Memphis, Tenn. Over his more than 36-year career, David held numerous leadership positions across the FedEx Express operating company in multiple regions, including chief operating officer and president - international, FedEx Express Asia Pacific chief financial officer, and regional president of the Asia Pacific region. Most recently as president and CEO of FedEx Express, David has been responsible for the leadership and direction of the FedEx Express group, which includes FedEx Express and TNT. Subramaniam has been with FedEx for more than 27 years and has held various e
CORRECTING and REPLACING The Dedica Anthology Completes Its Planned Refinancing7.12.2018 11:43 | Pressemelding
The first sentence of the release should read: Milan-based hotel group The Dedica Anthology is pleased to announce that it successfully completed its planned €337 million refinancing. (instead of Milan-based hotel group The Dedica Anthology is pleased to announce that today it successfully completed its planned €337 million refinancing). The corrected release reads: THE DEDICA ANTHOLOGY COMPLETES ITS PLANNED REFINANCING Milan-based hotel group The Dedica Anthology is pleased to announce that it successfully completed its planned €337 million refinancing. The lender is Blackstone Real Estate Debt Strategies, and the facilities will refinance legacy loans and provide additional capital for The Dedica Anthology – owned by global alternative investment firm Värde Partners – to invest significantly in its estate. London-based real estate specialist JLL advised Värde Partners on the transaction. Stephen Alden, CEO of The Dedica Anthology, commented: “We are delighted to have completed this c
The Dedica Anthology Completes Its Planned Refinancing7.12.2018 10:48 | Pressemelding
Milan-based hotel group The Dedica Anthology is pleased to announce that today it successfully completed its planned €337 million refinancing. The lender is Blackstone Real Estate Debt Strategies, and the facilities will refinance legacy loans and provide additional capital for The Dedica Anthology – owned by global alternative investment firm Värde Partners – to invest significantly in its estate. London-based real estate specialist JLL advised Värde Partners on the transaction. Stephen Alden, CEO of The Dedica Anthology, commented: “We are delighted to have completed this complex refinancing. Our own team, the board, our advisors and the lending group have worked hard in collaboration to achieve this excellent result. Our focus is now fully on building The Dedica Anthology brand, carrying out strategic renovation and restoration work on our distinctive properties, strengthening our team and growing our business.” Alessandro Grassivaro, CFO of The Dedica Anthology, added, “Dedica now